Navigation Links
Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
Date:10/14/2010

SEATTLE, Oct. 14 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) has provided an additional grant to fund clinical studies for the Company's Addiction program. This grant, which is for a total of approximately $3.6 million to be paid over a four-year period in equal amounts, will fund direct and indirect costs of Phase 2 clinical studies to be conducted by researchers at the New York State Psychiatric Institute (NYSPI). In Omeros' Addiction program, the Company is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPARgamma) agonists for the prevention and treatment of addiction to substances of abuse, such as opioids, nicotine and alcohol, as well as other compulsive behaviors, including eating disorders. Data from earlier European pilot clinical studies and animal models of addiction have demonstrated a previously unknown link between PPARgamma and addiction disorders.

Earlier this year, Omeros announced that NIDA agreed to fund substantially all of the costs of a Phase 2 clinical study to be conducted by NYSPI researchers to evaluate a PPARgamma agonist for the treatment of addiction to prescription opioids. The NIDA support announced today will be used to fund additional Phase 2 clinical studies to evaluate the effect of a PPARgamma agonist in combination with other agents on the use of heroin and cigarettes.  These clinical studies will also be conducted at the NYSPI and will be led by the recipients of this grant award, Dr. Sandra D. Comer and Dr. Adam Bisaga. Omeros will have the right to reference the data obtained from these studies for subsequent submissions to the FDA and will retain all other rights in connection with its Addiction program.

"This latest grant from NIDA underscores the potential of our Addiction program to yield a
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Omeros Secures $40 Million Committed Equity Financing Facility
2. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
3. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
4. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
5. Omeros Commences Initial Public Offering of Common Stock
6. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
9. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
10. Omeros and BlueCrest Announce $20 Million Debt Facility
11. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... As the weather warms, women everywhere are waiting for the ... make a statement with fashion, many change their makeup to ... mixes makeup and sweat to produce, and increase acne breakouts. ... warmer months, Adult Acne treatment , Probiotic Action shares ... to deter breakouts. , Recently, an article from ...
(Date:5/16/2013)... NEW YORK , May 16, ... a new market research report is ...   Competitor Analysis: ... Biosuperiors http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ...   The ...
(Date:5/16/2013)... BioInformatics LLC New Market Report – ... Current and Future Opportunities (13-004) , With barriers ... primary cells market continues to increase. In this study, ... often, how satisfied scientists are with commercially available primary ... rate. ,  , Additionally, terminally differentiated cells can ...
(Date:5/16/2013)... 2013 Dr. Stephen Y. Chou, Founder ... “Nanoimprint Lithography and Applications” at IEEE Nano 2013 in ... in 1995 by Chou, is becoming one of the ... combination of sub-10 nm resolution, large area, and low ... both R&D and manufacturing in a broad range of ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... FRANKLIN LAKES, N.J., March 27 BD (Becton,Dickinson ... global medical technology,company, and Direct Relief International, a ... joint volunteer,initiative to strengthen healthcare in Ghana. A ... to Ghana for three weeks and work side-by-side,with ...
... Siemens Will Showcase Its Portfolio of Cardiovascular ... Healthcare, (http://www.usa.siemens.com/healthcare ) will demonstrate how its ... are helping,to "Bring a New Rhythm to ... of the American College of Cardiology (ACC) ...
... Aimed at Developing New Screening Methods and Holds Significant, Potential for Early ... ... Killer, - Biomarker Project holds significant potential for new screening ... the disease before even the ...
Cached Biology Technology:BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 2BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana 3Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 2Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 3Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 4Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiology's Toughest Questions 5Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 2Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 3
(Date:5/16/2013)... years old give unprecedented insight into the evolutionary ... most species-rich groups among the modern bony fishes. ... from the Division of Paleontology and Geobiology at ... Ludwig-Maximilians-Universitaet (LMU) in Munich / Germany have completed ... assign to the group of bony fishes that ...
(Date:5/16/2013)... in Cameroon and the manager of San Diego Zoo ... prestigious Whitley award. The Whitley award is an ... because it celebrates the extraordinary achievements of some of ... Abwe was selected for the award due to his ... and its wildlife inhabitants., HRH The Princess Royal, the ...
(Date:5/15/2013)... in moderating gout risk, new research reveals that vitamin ... acid (urate) levels to a clinically significant degree in ... in combination with allopurinol, appears to have a weak ... according to the results published in the American College ... , Gout is an inflammatory arthritis that causes ...
Breaking Biology News(10 mins):Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3Vitamin C does not lower uric acid levels in gout patients 2
... Nov. 1, 2011Researchers at St. Michael,s Hospital have identified ... They also identified two possible treatments to prevent ... the development of new drugs to treat heart attacks ... Ni, found that the same kind of blood-clotting in ...
... people can exchange information instantaneously in the digital age, ... freely and rapidly exchange genetic material related to human ... gene transfer (HGT). In a paper appearing in ... by Eric Alm of MIT,s Department of Civil and ...
... Chinese Academy of Sciences found one new species, Aleurodaphis sinojackiae ... forms leaf galls on Jack trees ( Sinojackia xylocarpa ) and is ... ( Hemiptera , Aphididae , Hormaphidinae ). The ... . Aleurodaphis was established in 1917 by van der ...
Cached Biology News:Researchers pinpoint possible new cause for unexplained miscarriages 2MIT: Bacteria may readily swap beneficial genes 2MIT: Bacteria may readily swap beneficial genes 3